

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 64-081

FINAL PRINTED LABELING

NDC 0332-3206-24
15 Capsules
**CEFACTOR
CAPSULES USP**
250 mg

Lot #
Discard After
Keep tightly closed. Store at controlled
room temperature 15°-30°C (59°-86°F).
Mfd. by Biocraft Laboratories, Inc.
Elmwood Park, NJ 07407
1193

SEP 16 1996

NDC 0332-3206-24
15 Capsules
**CEFACTOR
CAPSULES USP**
250 mg

Each capsule contains cefaclor
monohydrate equivalent to
250 mg cefaclor.
CAUTION: Federal (USA) law prohibits
dispensing without prescription.



Each capsule contains cefaclor monohydrate equivalent to 250 mg cefaclor. Usual Adult Dosage: 250 mg three times a day. For severe infections, this dosage may be doubled. See accompanying literature.



N 0332-3206-24 2


100 Capsules
NDC 0332-3206-09
**CEFACTOR
CAPSULES USP**
250 mg
CAUTION: Federal (USA) law prohibits
dispensing without prescription.



Keep tightly closed.
Store at controlled room temperature 15°-30°C
(59°-86°F).
Dispense in a tight, light-resistant container.
Mfd. by Biocraft Laboratories, Inc.
Elmwood Park, NJ 07407
1193


LOT
EXP
9661 9 1 SEP

Each capsule contains cefaclor monohydrate equivalent to 250 mg cefaclor. Usual Adult Dosage: 250 mg three times a day. For severe infections, this dosage may be doubled. See accompanying literature.



N 0332-3206-09 9

500 Capsules
NDC 0332-3206-13
**CEFACTOR
CAPSULES USP**
250 mg




CAUTION: Federal (USA) law prohibits
dispensing without prescription.

Keep tightly closed.
Store at controlled room temperature 15°-30°C
(59°-86°F).
Dispense in a tight, light-resistant container.
Mfd. by Biocraft Laboratories, Inc.
Elmwood Park, NJ 07407
1193

LOT
EXP
9 1 1995

Each capsule contains cefaclor monohydrate equivalent to 250 mg cefaclor. Usual Adult Dosage: 250 mg three times a day. For severe infections, this dosage may be doubled. See accompanying literature.



N 0332-3206-13 6



**CEFACLOR
CAPSULES, USP**
250 mg and 500 mg

APR 16 1996

SEP 16 1996

DESCRIPTION

Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. It is chemically designated as 3-chloro-7-D-(2-phenylglycinamide)-3-cephem-4-carboxylic acid monohydrate.



$C_{15}H_{14}ClN_2O_4 \cdot H_2O$
MW 365.82

Each capsule contains cefaclor monohydrate equivalent to 250 mg (0.68 mmol) or 500 mg (1.36 mmol) cefaclor.

Inert ingredients: sodium starch glycolate and sodium stearoyl fumarate.

CAPSULE SHELL AND PRINT CONSTITUENTS: D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Red #40, gelatin, pharmaceutical glaze, propylene glycol, silicon dioxide, sodium lauryl sulfate, synthetic black iron oxide and titanium dioxide. The 250 mg capsule shell also contains black iron oxide and yellow iron oxide.

CLINICAL PHARMACOLOGY

Cefaclor is well absorbed after oral administration in fasting subjects. Total absorption is the same whether the drug is given with or without food; however, when it is taken with food, the peak concentration achieved is 50% to 75% of that observed when the drug is administered in fasting subjects and generally appears from three hours to 1 hour later. Following administration of 150-mg, 500-mg, and 1-g doses to fasting subjects, average peak serum levels of approximately 7, 13, and 23 µg/mL, respectively were obtained within 30 to 60 minutes. Approximately 50% to 65% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours. During this 8-hour period, peak urine concentrations following the 250-mg, 500-mg and 1-g doses were approximately 600, 900, and 1,000 µg/mL, respectively. The serum half-life in normal subjects is 0.8 to 0.9 hour. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours. Excretion pathways in patients with markedly impaired renal function have not been determined. Hemodialysis shortens the half-life by 25% to 30%.

Microbiology *in vitro* tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor is active *in vitro* against most strains of clinical isolates of the following organisms:

Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains (when tested by *in vitro* methods) (arbor crest).

half-life of cefactor is slightly prolonged in those with moderate impairment of renal function. The plasma half-life of the intact molecule is 2.3 to 2.8 hours. Excretion pathways in patients with markedly impaired renal function have not been determined. Hemodialysis shortens the half-life by 25% to 30%.

Microbiology—In vitro tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefactor is active in vitro against most strains of clinical isolates of the following organisms:

Staphylococci, including coagulase-positive and coagulase-negative and penicillinase-producing strains (when tested by *in vitro* methods), exhibit cross-resistance between cefactor and methicillin.

Streptococcus pyogenes (Group A β -hemolytic streptococci)

Streptococcus pneumoniae

Moraxella (Branhamella) catarrhalis

Haemophilus influenzae, including β -lactamase-producing ampicillin-resistant strains.

Escherichia coli

Proteus mirabilis

Klebsiella sp.

Citrobacter diversus

Neisseria gonorrhoeae

Propionibacterium acnes and *Bacteroides sp.* (excluding *Bacteroides fragilis*)

Peptococci:

Peptostreptococci:

Note: *Pseudomonas sp.*, *Acinetobacter calcoaceticus* (formerly *Mima sp.* and *Herellea sp.*) and most strains of enterococci (*Enterococcus faecalis* [formerly *Streptococcus faecalis*], group D streptococci), *Enterobacter sp.*, middle-positive *Proteus*, and *Serratia sp.* are resistant to cefactor. When tested by *in vitro* methods, staphylococci exhibit cross-resistance between cefactor and methicillin-type antibiotics.

Disk Susceptibility Tests—Quantitative methods that require measurement of zone diameters give the most precise estimates of antibiotic susceptibility. One such procedure has been recommended for use with disks for testing susceptibility to cephalosporins. The currently accepted zone diameter interpretative criteria for the cephalothin disk are appropriate for determining bacterial susceptibility to cefactor. With this procedure, a report from the laboratory of "resistant" indicates that the infecting organism is not likely to respond to therapy. A report of "intermediate susceptibility" suggests that the organism would be susceptible if the infection is confined to tissues and fluids (e.g., urine) in which high antibiotic levels can be obtained or if high dosage is used.

INDICATIONS AND USAGE

Cefactor capsules are indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms.

Oral Infections caused by *S. pneumoniae*, *H. influenzae*, staphylococci, and *S. pyogenes* (group A β -hemolytic streptococci).

Lower respiratory infections, including pneumonia, caused by *S. pneumoniae*, *H. influenzae*, and *S. pyogenes* (group A β -hemolytic streptococci).

Upper respiratory infections, including pharyngitis and tonsillitis, caused by *S. pyogenes* (group A β -hemolytic streptococci).

Note: Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefactor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefactor in the subsequent prevention of rheumatic fever are not available at present.

Urinary tract infections, including pyelonephritis and cystitis, caused by *E. coli*, *P. mirabilis*, *Klebsiella sp.*, and coagulase-negative staphylococci.

Skin and skin structure infections caused by *Staphylococcus aureus* and *S. pyogenes* (group A β -hemolytic streptococci).

Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefactor.

CONTRAINDICATIONS

Cefactor is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

WARNINGS

IN PENICILLIN-SENSITIVE PATIENTS, CEPHALOSPORIN ANTIBIOTICS SHOULD BE ADMINISTERED CAUTIOUSLY. THERE IS CLINICAL AND LABORATORY EVIDENCE OF PARTIAL CROSS-ALLERGICITY OF THE PENICILLINS AND THE CEPHALOSPORINS AND THERE ARE INSTANCES IN WHICH PATIENTS HAVE HAD REACTIONS INCLUDING ANAPHYLAXIS, TO BOTH DRUG CLASSES.

Antibiotics including cefactor.

and *S. typhimurium* (includes
caused by *Staphylococcus aureus*
and *S. pyogenes* (group A β -
hemolytic streptococci))

Appropriate culture and susceptibility
studies should be performed to
determine susceptibility of the
causative organism to cefaclor.

CONTRAINDICATIONS

Cefaclor is contraindicated in
patients with known allergy to the
cephalosporin group of antibiotics

WARNINGS

IN PENICILLIN-SENSITIVE PATIENTS, CEPHALOSPORIN ANTIBIOTICS SHOULD BE ADMINISTERED CAUTIOUSLY. THERE IS CLINICAL AND LABORATORY EVIDENCE OF PARTIAL CROSS-ALLERGENICITY OF THE PENICILLINS AND THE CEPHALOSPORINS AND THERE ARE INSTANCES IN WHICH PATIENTS HAVE HAD REACTIONS, INCLUDING ANAPHYLAXIS, TO BOTH DRUG CLASSES.

Antibiotics, including cefaclor, should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to drugs.

Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics (including macrolides, semisynthetic penicillins, and cephalosporins); therefore, it is important to consider its diagnosis in patients who develop diarrhea in association with the use of antibiotics. Such colitis may range in severity from mild to life threatening.

Treatment with broad-spectrum antibiotics alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is a primary cause of antibiotic-associated colitis.

Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, management should include sigmoidoscopy, appropriate bacteriologic studies, and fluid, electrolyte, and protein supplementation. When the colitis does not improve after the drug has been discontinued, or when it is severe, oral vancomycin is the drug of choice for antibiotic-associated pseudomembranous colitis produced by *C. difficile*. Other causes of colitis should be ruled out.

PRECAUTIONS

General—If an allergic reaction to cefaclor occurs, the drug should be discontinued and, if necessary, the patient should be treated with appropriate agents, e.g., pressor amines, antihistamines, or corticosteroids.

Prolonged use of cefaclor may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential if superinfection occurs during therapy; appropriate measures should be taken.

¹ Bauer AW, Kirby WMM, Sherris JC and Turck M. Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol* 1966;45:483. Standardized disk susceptibility test. *Federal Register* 1974;39:19182-19184.

Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs' test may be due to the drug.

Cefactor should be administered with caution in the presence of markedly impaired renal function. Since the half-life of cefactor in anuria is 2.3 to 2.8 hours, dosage adjustments for patients with moderate or severe renal impairment are usually not required. Clinical experience with cefactor under such conditions is limited; therefore, careful clinical observation and laboratory studies should be made.

As with other β -lactam antibiotics, the renal excretion of cefactor is inhibited by probenecid.

As a result of administration of cefactor, a false-positive reaction for glucose in the urine may occur. This has been observed with Benedict's and Fehling's solutions and also with Chemstrip[®] tablets but not with Tes-Tape[®] (Glucose Enzymatic Test Strip, USP).

Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Usage in Pregnancy—Pregnancy Category B—Reproduction studies have been performed in mice and rats at doses up to 12 times the human dose and in ferrets given 3 times the maximum human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefactor. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, the drug should be used during pregnancy only if clearly needed.

Nursing Mothers—Small amounts of cefactor have been detected in mother's milk following administration of single 500-mg doses. Average levels were 0.18, 0.20, 0.21, and 0.16 $\mu\text{g/mL}$ at 2, 3, 4, and 5 hours respectively. Trace amounts were detected at 1 hour. The effect on nursing infants is not known. Caution should be exercised when cefactor is administered to a nursing woman.

Pediatric Use—Safety and effectiveness of this product for use in infants less than 1 month of age have not been established.

ADVERSE REACTIONS

Adverse effects considered to be related to therapy with cefactor are listed below.

Hypersensitivity reactions have been reported in about 13% of patients and include morbilliform eruptions (1 in 100), pruritus, urticaria, and positive Coombs' tests each occur in less than 1 in 200 patients.

Cases of serum-sickness-like reactions have been reported with the use of cefactor. These are characterized by findings of erythema multiforme, rashes, and other skin manifestations accompanied by arthralgias, with or without fever, and differ from classic serum sickness in that there is infrequently associated lymphadenopathy and proteinuria, no circulating immune complexes, and no evidence of date of sequelae of the reaction. While further investigation is ongoing, serum-sickness-like reactions appear to be due to hypersensitivity and more often occur during or following a second (or subsequent) course of therapy with cefactor. Such reactions have been reported more frequently in children than in adults with an overall occurrence ranging from 1 in 200 (0.5%) in one focused trial to 2 in 8,348 (0.024%) in overall clinical trials (with an incidence in children in clinical trials of 0.055% to 1 in 38,000 (0.003%) in spontaneous event reports). Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy; occasionally these reactions have resulted in hospitalization, usually of short duration (median hospitalization = 2 to 3 days, based on postmarketing surveillance studies). In those requiring hospitalization, the symptoms have ranged from mild to severe at the time of admission with more of the severe reactions occurring in children. Antihistamines and glucocorticoids appear to enhance resolution of the signs and symptoms. No serious sequelae have been reported.

More severe hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis have been reported rarely. Anaphylaxis may be more common in patients with a history of penicillin allergy.

Gastrointestinal symptoms occur in about 2.5% of patients and include diarrhea (1 in 70).

Symptoms of pseudomembranous colitis may appear either during or after antibiotic treatment. Nausea and vomiting have been reported.

5

multiforme, rashes, and other skin manifestations accompanied by arthralgia/arthralgia, with or without fever, and differ from classic serum sickness in that there is infrequently associated lymphadenopathy and proteinuria, no circulating immune complexes, and no evidence to date of sequelae of the reaction. While further investigation is ongoing, serum-sickness-like reactions appear to be due to hypersensitivity and more often occur during or following a second (or subsequent) course of therapy with cefaclor. Such reactions have been reported more frequently in children than in adults with an overall occurrence ranging from 1 in 200 (0.5%) in one focused trial to 2 in 8,348 (0.024%) in overall clinical trials (with an incidence in children in clinical trials of 0.055% to 1 in 38,000 (0.003%) in spontaneous event reports. Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy; occasionally these reactions are resulted in hospitalization, usually of short duration (median hospitalization = 2 to 3 days, based on postmarketing surveillance studies). In those requiring hospitalization, the symptoms have ranged from mild to severe at the time of admission with more of the severe reactions occurring in children. Antihistamines and glucocorticoids appear to enhance resolution of the signs and symptoms. No serious sequelae have been reported.

More severe hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis have been reported rarely. Anaphylaxis may be more common in patients with a history of penicillin allergy.

Gastrointestinal symptoms occur in about 2.5% of patients and include diarrhea (1 in 70).

Symptoms of pseudomembranous colitis may appear either during or after antibiotic treatment. Nausea and vomiting have been reported rarely. As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported rarely.

Other effects considered related to therapy included eosinophilia (1 in 50 patients), genital pruritus or vaginitis (less than 1 in 100 patients), and, rarely, thrombocytopenia or reversible interstitial nephritis.

Causal Relationship Uncertain—

CNS—Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hyperreflexia, dizziness, hallucinations, and somnolence have been reported.

Transient abnormalities in clinical laboratory test results have been reported. Although they were of uncertain etiology, they are listed below to serve as alerting information for the physician.

Hepatic—Slight elevations of AST (SGOT), ALT (SGPT), or alkaline phosphatase values (1 in 40).

Hematopoietic—As has also been reported with other 8-lactam antibiotics, transient lymphocytosis, leukopenia, and, rarely, hemolytic anemia and reversible neutropenia of possible clinical significance.

There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly.

Renal—Slight elevations in BUN or serum creatinine (less than 1 in 500) or abnormal urinalysis (less than 1 in 200).

OVERDOSEAGE

Signs and Symptoms—The toxic symptoms following an overdose of cefaclor may include nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose related. If other symptoms are present, it is probable that they are secondary to an underlying disease state, an allergic reaction, or the effects of other intoxication.

Treatment—To obtain up-to-date information about the treatment of overdose a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the *Physicians' Desk Reference (PDR)*. In managing overdose consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

Unless 5 times the normal dose of cefaclor has been ingested, gastrointestinal decontamination will not be necessary.

Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain within acceptable limits the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage. Consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.

Forced diuresis, peritoneal dialysis, hemodialysis or charcoal hemoperfusion have not been established.

6
Rena—Dose
serum creatinine less than 1 in
500) or abnormal urinalysis (less
than 1 in 200)

OVERDOSE

Signs and Symptoms—The toxic symptoms following an overdose of cefaclor may include nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose related. If other symptoms are present, it is probable that they are secondary to an underlying disease state, an allergic reaction, or the effects of other medication.

Treatment—To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians' Desk Reference (PDR). In managing overdoses, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

Unless 5 times the normal dose of cefaclor has been ingested, gastrointestinal decontamination will not be necessary.

Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage. Consider charcoal mixed or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.

Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of cefaclor.

DOSE AND ADMINISTRATION

Cefaclor capsules are administered orally.

Adults—The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.

Cefaclor may be administered in the presence of impaired renal function. Under such a condition, the dosage usually is unchanged (see **PRECAUTIONS**).

In the treatment of β -hemolytic streptococcal infections a therapeutic dosage of cefaclor should be administered for at least 10 days.

HOW SUPPLIED

Cefaclor Capsules, USP are supplied as follows:

250 mg White opaque cap and gray opaque body imprinted "BID-CRAFT 223" in bottles of 15 (NDC 0332-3206-24), 100 (NDC 0332-3206-09), 500 (NDC 0332-3206-13)
500 mg Red opaque cap and white opaque body imprinted "BID-CRAFT 224" in bottles of 15 (NDC 0332-3210-24), 100 (NDC 0332-3210-09), 500 (NDC 0332-3210-13)

Store at controlled room temperature 15° - 30°C (59° - 86°F)

CAUTION—Federal (USA) law prohibits dispensing without prescription.

Manufactured by
Bicraft Laboratories, Inc.
Eimwood Park, NJ 07407

April 1994



NDC 0332-3210-24
15 Capsules
**CEFACTOR
CAPSULES USP**

500 mg

Lot # **SEP 16 1996**

Discard After

Keep tightly closed. Store at controlled
room temperature 15°-30°C (59°-86°F).

Mfd. by: Biocraft Laboratories, Inc.
Elmwood Park, NJ 07407
1193

NDC 0332-3210-24
15 Capsules
**CEFACTOR
CAPSULES USP**

500 mg

APPROVED

CAUTION: Federal (USA) law prohibits
dispensing without prescription.



Each capsule contains cefaclor
500 mg (equivalent to 250 mg cefaclor monohydrate).
See accompanying literature for complete prescribing information.
Keep tightly closed. Store at controlled room temperature 15°-30°C (59°-86°F).
Mfd. by: Biocraft Laboratories, Inc.
Elmwood Park, NJ 07407
1193



N 0332-3210-24 9

LOT
EXP 9661 9 1 1193

Mfd. by: Biocraft Laboratories, Inc.
Elmwood Park, NJ 07407
1193

Dispense in a light, light-resistant container.
Store at controlled room temperature 15°-30°C
(59°-86°F).
Keep tightly closed.

500 Capsules

NDC 0332-3210-13


**CEFACTOR
CAPSULES USP**

500 mg

CAUTION: Federal (USA) law prohibits
dispensing without prescription.



Each capsule contains cefaclor monohydrate
equivalent to 500 mg cefaclor.
Usual Adult Dosage: 250 mg three times a day.
For severe infections, the dosage may be
doubled. See accompanying literature.



N 0332-3210-13 3